Back to Search
Start Over
One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision
- Source :
- Ophthalmology Retina. 3:1107-1109
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Safety of the intravitreal plasma kallikrein inhibitor (KVD001) was tested in patients with diabetic macular edema. KVD001 was well tolerated. Systemic absorption was low. Improvement of retinal edema and vision occurred in most study eyes.
- Subjects :
- 0303 health sciences
medicine.medical_specialty
Visual acuity
genetic structures
Reduced vision
business.industry
Diabetic macular edema
Retinal
eye diseases
03 medical and health sciences
Ophthalmology
Plasma kallikrein inhibitor
chemistry.chemical_compound
0302 clinical medicine
chemistry
Edema
030221 ophthalmology & optometry
medicine
In patient
sense organs
Open label
medicine.symptom
business
030304 developmental biology
Subjects
Details
- ISSN :
- 24686530
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- Ophthalmology Retina
- Accession number :
- edsair.doi...........bc6555ac14ddc25366b0c0a0ebb800ad
- Full Text :
- https://doi.org/10.1016/j.oret.2019.07.006